Finance JournalistThe Financial Stability Oversight Council has taken a noticeably softer approach to crypto assets in its 2025 annual report.
The report marks a shift from earlier warnings that digital assets posed systemic risks to financial stability.
FSOC linked the change in tone to new federal regulation and evolving political support for the crypto industry.
Twenty One Capital's highly anticipated debut on the New York Stock Exchange ended with a sharp sell-off, highlighting growing investor restraint toward Bitcoin (CRYPTO:BTC)-heavy public companies.
Trading under the ticker XXI, the stock fell by almost 20% on its first day, defying expectations fuelled by its sizeable Bitcoin treasury and prominent institutional backers.
The US Securities and Exchange Commission has issued fresh guidance aimed at helping retail investors better protect their cryptocurrency holdings as adoption continues to rise.
The guidance was published on December 12 by the SEC’s Office of Investor Education and Advocacy in the form of a new Investor Bulletin.
Strategy retained its position in the Nasdaq 100 following the index’s annual rebalancing, marking its first successful review since joining the benchmark in December last year and signalling continued acceptance by major equity indices.
The company, formerly known as MicroStrategy, stood out during the rebalance due to its unconventional balance sheet, which is heavily weighted towards Bitcoin (CRYPTO:BTC) rather than traditional operating assets.
The global stablecoin market reached a new all-time high in the second week of December, surpassing $310 billion as fiat-pegged tokens regained momentum.
Data from DefiLlama shows the stablecoin sector peaked at approximately $310.09 billion on Saturday, marking its strongest level to date.
Rhythm Biosciences (ASX:RHY) has commenced commercialisation of its flagship blood-based colorectal cancer test, ColoSTAT, following the update and renewal of its ISO15189:2022 laboratory accreditation.
The test will initially be offered as an alternative for symptomatic individuals where stool-based screening is unsuitable, unavailable, or not preferred, addressing a significant unmet clinical need.
ABx Group (ASX:ABX) has been granted a new five-year exploration licence, EL25/2022, strengthening its position in a highly prospective rare earths region in northern Tasmania.
The 18km2 tenement sits between the company's Rubble Mound and Wind Break deposits, part of ABx's 89-million-tonne resource averaging 844 ppm total rare earth oxides.
